Introduction
Individualizing therapy for patients who are treated with pharmaceutical agents is an overarching goal of basic and clinical research in this first part of the twenty-first century. In no area of medicine is this goal more critical than in medical oncology. Genetic variation in genes encoding proteins involved in the metabolism and transport of drugs may account for some of the wide variation observed in the response to, and toxicity from, anticancer agents.
Pharmacogenetic research holds the promise of reducing the unpredictable inter-individual variability in the efficacy and toxicity from using chemotherapy drugs.
Enzymes and transporters mediate the absorption, distribution, metabolism and excretion of endogenous as well as exogenous substrates, including drugs. However, for only a relatively small number of absorption, distribution, metabolism and excretion genes have single nucleotide polymorphisms (SNPs) and other genetic variations been identified that mediate the efficacy and toxicity of chemotherapy drugs. These include irinotecan and UGT1A1, 6-mercaptopurine and thiopurine methyltransferase, 5-fluoruracil and dihydropyrimidine dehydrogenase and tamoxifen and cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6).
1 Docetaxel (Taxotere) is a semisynthetic taxane that is currently used as first-line therapy in castration-resistant prostate cancer (CRPC). It is thought that the major route of metabolism is through the CYP3A family of enzymes. [2] [3] [4] The pharmacokinetic profile of docetaxel shows wide interindividual variability, with measures such as clearance and area under the concentration curve varying as much as sixfold between patients. 5, 6 Even in an ethnically homogenous patient population, variability is as high as 3.5-fold. 7 Research using probes of CYP3A4 activity have been unsuccessful in explaining this large variation. [7] [8] [9] [10] In fact, the activity of CYP3A4/3A5 accounts for as little as twothirds of the inter-individual variable pharmacology of the drug. 6, 11 This led researchers to look at other metabolizing enzymes, including glutathione-S-transferases, as well as drug transporters such as ABCB1 (P-glycoprotein), to help explain this large variability in drug pharmacology. [11] [12] [13] [14] The pharmacogenetic factors mediating docetaxel pharmacokinetics have not been fully characterized. 14 We have previously proposed that a more comprehensive analysis into the expression and genetic polymorphisms of multiple drug enzymes and transporters may improve our understanding of the pharmacokinetics of docetaxel. 15 Thalidomide, a potent teratogen that causes dysmelia in humans, has been approved for the treatment of multiple myeloma and is under active clinical analysis for its use in treating other malignancies. The anticancer mechanism of action of thalidomide is complex and has not yet been fully charecterized. In vitro data suggest that it inhibits angiogenesis. Non-enzymatic spontaneous hydrolysis is a major route of metabolism, with at least 12 different products identified by this process. 16 However, enzymatic activation of these hydrolysis products is necessary for thalidomide to exert its anticancer activity. [17] [18] [19] Two metabolites, 5-hydroxythalidomide and 5 0 -hydroxythalidomide, are formed by CYP2C19 and to a lesser extent CYP2B6. 20 CYP1A1 may have a role in parent drug activation. 21 Other metabolism products, including dihydroxylated and glucuronide conjugates, have been found in animal models. 22 Past pharmacogenetic studies analyzing whether SNPs in CYP2C19 accounted for the inter-individual variation in pharmacokinetics and toxicities have been inconclusive. 19, 23 Testing for the presence of genetic variations and SNPs is typically performed by DNA amplification using PCR and sequencing of specific gene fragments. This work is specialized and labor intensive, which in turn limits the institutions and investigators who can pursue genotyping and pharmacogenetic research. One of the main obstacles facing pharmacogenetic researchers is the lack of a proven, scalable genotyping technology that screens for SNPs in multiple genes with sufficient sensitivity and high-throughput capabilities to be useful in translational and clinical research. The new Affymetrix drug-metabolizing enzyme and transporter (DMET) genotyping platform (Affymetrix, Inc., Santa Clara, CA, USA) screens for 1256 genetic variations in 170 absorption, distribution, metabolism and excretion genes, including 50 CYP450 genes, 72 non-CYP genes, 39 transporters and 9 other proteins involved in drug disposition (Table 1) . 24 We tested this new genotyping platform, termed DMET, using patient samples and clinical data from our previously completed phase II trial in patients with CRPC to analyze the pharmacogenetics of thalidomide and docetaxel.
Patients and methods

Patients
Patients diagnosed with CRPC were enrolled in a randomized phase II clinical trial comparing docetaxel to docetaxel with thalidomide. The results of this trial have been previously reported. 25 In brief, 74 patients with CRPC were enrolled with a 2:1 randomization to receive either docetaxel and thalidomide, or docetaxel alone. Docetaxel was dosed at 30 mg m -2 weekly for 3 weeks followed by a 1-week rest. For patients assigned to the combination arm, they received docetaxel on the same schedule, as well as thalidomide at 200 mg orally each day. In all, 49 patients were in the combination arm and 25 patients were in the control arm. 25 The study was approved by the institutional review board of the National Cancer Institute.
Response to treatment was determined using the prostatespecific antigen Working Group consensus criteria of a drop in serum prostate-specific antigen of X50% with no other evidence of disease progression. Toxicities were graded using the Common Toxicity Criteria (version 2.0) of the Cancer Therapy Evaluation Program/National Cancer Institute. For this pharmacogenetic study, only adverse reactions graded as 3 (no grade 4 adverse events were experienced on this trial) and identified as being possibly, probably or definitely related to study medications were included. Events of bone pain, which is common in this patient population, as well as events of hyperglycemia (which were likely caused by the use of dexamethasone as a docetaxel pre-medication) were not included. Finally, events of venous thrombosis were not included because the trial was modified to add lowmolecular-weight heparin to patients receiving thalidomide after an interim analysis found a high rate of such events early in the trial. Toxicity was used as a pharmacodynamic measure as well as a surrogate marker for drug pharmacokinetics as, at least in the case of docetaxel, clearance and pharmacokinetics have been previously found to correlate well with drug toxicity. [26] [27] [28] Patient samples For 47 of the 74 originally enrolled patients, stored buffy coat samples were archived and available for DNA extraction. This included 33 patients on the combination arm of the trial and 14 patients on the docetaxel-alone arm. Blood was collected from patients, and the buffy coat layers were resuspended and frozen in Trizol (Invitrogen, Carlsbad, CA, USA). Genomic DNA was extracted from serum or white blood cell buffy coat layers of whole blood from patients using either the QiAamp Ultrasens Viral DNA kit (serum) or the QIAamp DNA blood kit (buffy coat) as described by the manufacturer (Qiagen, Valencia, CA, USA).
Preparation and processing of the drug-metabolizing enzyme and transporter platform (DMET) DNA processing and genotype identification for each patient sample were performed using the Affymetrix DMET platform as recently described. 24 Genotypes were determined for each SNP site, reported as homozygous wild-type, heterozygous, homozygous variant or 'no call'. Four samples were run in duplicate and the repeatability from both experiments was compared.
Direct genotyping
Genotyping was conducted through direct sequencing for variants in eight genes that were previously thought to correlate with prostate cancer risk or the pharmacology of docetaxel and thalidomide (Table 5) . PCR was performed on gene fragments for each variant site using primers and PCR conditions as previously performed for CYP17, 29 CYP2C19, Table 1 Genes included in the DMET 1.0 panel
P450 Enzymes
Non -P450 enzymes  Transporters  Other   CYP1A1  CYP4F2  ADH1A  CROT  NQO1  ABCB1  SLC15A2  AHR  CYP1A2  CYP4F3  ADH1B  DYPD  SULT1A1  ABCB4  SLC16A1  NR1I2  CYP1B1  CYP4F8  ADH4  EPHX1  SULT1A2  ABCB7  SLC19A1  NR3C1  CYP2A13  CYP4Z1  ADH5  FMO1  SULT1A3  ABCB11  SLC22A1  PPARD  CYP2A6  CYP46A1  ADH6  FMO2  SULT1B1  ABCC1  SLC22A2  PPARG  CYP2A7  CYPA1  ADH7  FMO3  SULT1C1  ABCC2  SLC22A3  RALBP1  CYP2B6  CYP51A1  ALDH1A1  FMO4  SULT1C2  ABCC3  SLC22A4  RPL13  CYP2B7P1  CYP7A1  ALDH2  FMO5  SULT1E1  ABCC4  SLC22A5  SPG7  CYP2C9  CYP7B1  ALDH3A1  FMO6  SULT2A1  ABCC5  SLC22A6  XDH  CYP2C8  CYP8A1  AOX1  GSTA1  SULT2B1  ABCC6  SLC22A8  CYP2C19  CYP8B1  COA  GSTA2  SULT4A1  ABCG2  SLC28A1  CYP2C18  CYP11A1  CHST1  GSTA3  TPMT  ATP7A  SLC28A2  CYP2D6  CYP11B1  CHST2  GSTA4  UGT1A1  ATP7B  SLC28A3  CYP2E1  CYP11B2  CHST3  GSTA5  UGT1A3  SLC5A6  SLC29A1  CYP2F1  CYP17A1  CHST4  GSTM2  UGT1A4  SLC7A5  SLC29A2  CYP2J2  CYP19A1  CHST5  GSTM3  UGT1A6  SLC7A7  SLCO1A2  CYP281  CYP20A1  CHST6  GSTM4  UGT1A7  SLC10A1  SLCO1B1  CYP3A4  CYP21A2  CHST7  GSTO1  UGT1A8  SLC10A2  SLC1B3  CYP3A43  CYP24A1  CHST8  GSTP1  UGT2A1  SLC13A1  SLCO2B1  CYP3A5  CYP26A1  CHST9  HNMT  UGT2B11  SLC15A1  CYP3A7  CYP26C1  CHST10  MAOB  UGT2B15  CYP4A11  CYP27A1  CHST11  NAT1  UGT2B28  CYP4B1  CYP27B1  CHST13  NAT2  UGT2B4  CYP4F11  CYP39A1  COMT  NNMT  UGT8  CYP4F12 POR Abbreviations: DMET, drug-metabolizing enzymes and transporters; SNP, single-nucleotide polymorphism. The DMET assay and panel genotype samples for variations in 170 drug disposition genes, including 50 CYP450 genes, 72 non-CYP genes, 39 transporters and 9 other proteins involved in drug disposition. Assay genotyping identifies homozygote wild-type, homozygote variant or heterozygote alleles in 1256 SNPs and other genetic variation sites in these genes.
Pharmacogenetics of docetaxel and thalidomide JF Deeken et al performed, followed by a final extension step of 7 min at 72 1C. Direct nucleotide sequencing PCR was conducted using the Big Dye Terminator Cycle Sequencing Ready Reaction kit V1.1 on an ABI Prism 3130 Â l genetic analyzer (Applied BioSystems). The primer sequences for these reactions were as follows: F2 5 0 -TGGCTTTGCCGGTGAGGA TGC-3 0 and R2 5 0 -GCAGTCAGCAAGGAGCCCAG-3 0 . Genotyping results by direct sequencing were previously reported and not found to correlate with clinical parameters. 25 
Statistical analysis
In an exploratory manner, the association between the SNP parameters and clinical response or toxicity were tested using Mehta's modification to Fisher's exact test. 35 Results of potential interest were limited to those in which the P-value was o0.01. P-values o0.001 would suggest even stronger association. Results are to be interpreted as hypothesis generating and in the context of a large number of exploratory evaluations performed.
Results
Patients
Of the 75 patients in the original study, sufficient DNA was available from 47 individuals. Demographic and clinical data on these patients are presented in Table 2 . The proportion of patients in each arm differed from the original 2:1 randomization, with slightly more patients on the combination arm (70 vs 67% in the parent study). Of the 14 patients who received docetaxel alone and were included in this pharmacogenetic study, 50% had a clinical response (partial or complete response), compared with a response rate of 37% in the overall study. Of the patients who received thalidomide and docetaxel, 73% of the patients included in this study had a clinical response compared with 53% in the parent trial. Whether a sample was archived and was of sufficient volume to enable DNA extraction was in no way related to the patient's response on the trial, and the higher response rates in this subset of patients cannot be readily explained. Toxicities experienced during the trial of grade 3 are listed in Table 3 , along with the percentage of study patients experiencing each toxicity.
DNA extraction and processing of the drug-metabolizing enzyme and transporter platform (DMET) Extracted DNA content from archived samples ranged between 3.0 and 930.9 ng. Although the recommended The original trial consisted of 25 patients receiving monotherapy, and 49 patients receiving the combination. There were 9/24 (37.5%) responses for the single agent, and 25/47 (53%) responses for the combination. 25 We included the maximum number of patients from the original trail who had a sufficiently large DNA sample for analysis with DMET. Characteristics of the 47 patients in this pharmacogenetic study. The parent study enrolled 75 patients in a 2:1 randomization between the two arms. Response rates using the prostate-specific antigen (PSA) Working Group consensus criteria were slightly higher in the subset of patients included in this study when compared with the patients in the parent study. Type and incidence rates of adverse reactions included in the toxicity analysis of the study using the National Cancer Institute (NCI) Common Toxicity Criteria (version 2.0). Only adverse events graded as 3 (no grade 4 adverse reactions were experienced on this trial), and those that were judged to be possibly, probably or definitely related to study medication were included. Single-nucleotide polymorphisms in the 170 DMET genes were identified. An SNP is defined as a genetic variant that occurs in at least 1% of a population. Frequency of the variant alleles was in general o10% (or 490% in those cases in which the reference 'wild-type' allele is the less common one). For 373 of the 1256 polymorphisms, or 30% of all loci, variant allelic frequencies were between 10 and 90% ( Figure 1 ).
Single-nucleotide polymorphisms (SNPs) associated with clinical response
In an initial screening procedure that used the generalized Fisher's exact test, 28 SNPs were identified in which the P-value was o0.05. Given the exploratory nature of this study, and to limit false-positive results, we further limited reported results to those with a P-value of o0.01. Using this criterion, 10 SNPs in three genes were found to be associated with response to therapy: PPAR-d, sulfotransferase family, cytosolic, 1C, member 2 (SULT1C2) and carbohydrate (chondroitin 6) sulfotransferase 3 (CHST3) ( Table 4) .
Single-nucleotide polymorphisms (SNPs) and toxicity
For toxicities from therapy, 11 SNPs in eight genes were found to be associated at a significance level of Po0.01 (Table 4) . These included two SNPs in spastic paraplegia 7 (pure and complicated autosomal recessive) (SPG7), three in CHST3 and single SNPs in CYP2D6, N-acetyltransferase 2 (arylamine N-acetyltransferase) (NAT2), ATP-binding cassette, sub-family C (CFTR/MRP), member 6 (ABCC6), ATPase, Cu þ þ transporting, alpha polypeptide (ATP7A), cytochrome P450, family 4, subfamily B, polypeptide 1 (CYP4B1) and solute carrier family 10 (sodium/bile acid cotransporter family), member 2 (SLC10A2). There was no association between patients with the CYP3A5*3C genotype, a poor metabolizing phenotype previously found to be associated with docetaxel pharmacology, and docetaxel toxicities (P ¼ 0.51). No other variant in CYP3A5 or CYP3A4 was associated with toxicity (data not shown).
Genotyping with the drug-metabolizing enzyme and transporter platform (DMET) versus direct sequencing genotyping Genetic variations in eight genes were identified using direct sequencing, and the results were compared with those results using the DMET platform. Concordance rates between these results ranged between 96 and 100% ( Table 5 ). All of the polymorphisms in Tables 4 and 5 were equally distributed across the two trial arms (P40.05; generalized Fisher's exact test). It is to be noted that in cases in which there were disagreements between the two result sets, and sufficient DNA was available, patient samples were resequenced. In each case tested, the initial results found by direct sequencing were found to be in error, and the results from the DMET platform processing were confirmed (data not shown).
Discussion
We present the findings from an exploratory pharmacogenomic study that related SNPs with the efficacy and toxicity of docetaxel and thalidomide used in a clinical trial of patients with CRPC. These data revealed that polymorphisms in three genes (that is, PPARd, SULT1C2 and CHST3) were associated with clinical outcome measures whereas polymorphisms in eight genes (that is, SPG7, CHST3, CYP2D6, NAT2, ABCC6, ATP7A, CYP4B1 and SLC10A2) were associated with toxicity. To our knowledge, these associations represent novel genes that may be related to either thalidomide-or docetaxel-based therapy, although this remains unclear given that no reports have indicated that any of the above genes are involved in the metabolism or disposition toward either agent. Moreover, the allelic variations in genes that are known to be involved in metabolism, transport and activity of docetaxel and thalidomide were not associated with any of the study end points. Thus, further studies are warranted to validate and explore these relationships, and we can only speculate as to why such strong relationships exist. Although all of these genes may be related to drug metabolism directly, and thus could be related to pharmacokinetics, they also participate in pathways that may affect drug action and could therefore be involved in pharmacodynamic interactions as well. Finally, some of these alleles may be related to disease state and not necessarily alter drug metabolism or disposition.
Peroxisome proliferator-activated receptor-d, one of three members of the PPAR family, is a ligand-activated transcription factor that forms heterodimers with the retinoid X receptor, which then binds to peroxisome proliferator response elements. The gene product has been identified for its role in lipid and cholesterol metabolism, 36 whereas the polymorphisms in the gene have been related to inter-individual variation in cholesterol metabolism, 37 insulin sensitivity, 38 psychological disorders 39 and reduced height. 40 Although no study has yet evaluated PPARd SNPs in relation to antiangiogenesis therapy, PPARd gene expression is a major hub node in the angiogesis network, 41 thus opposing thalidomide action. Given that we observed strong relationships with several SNPs in PPARd in only those patients who received both docetaxel and thalidomide, but not docetaxel alone, it seems that allelic variation in PPARd may influence therapeutic efficacy of the antiangiogenesis agent, thalidomide. However, this relationship is unclear as PPARd is a nuclear receptor that is responsible for the induction of genes involved in metabolic pathways as well.
Carbohydrate (chondroitin 6) sulfotransferase 3 encodes a member of the carbohydrate sulfotransferase family, termed chondroitin 6-O-sulfotransferase, as it is known to transfer sulfate groups from 3 0 -phosphoadenosine 5 0 -phosphosulfate to the six position of N-acetylgalactosamine of chondroitin. CHST3 is involved in extracellular matrix remodeling, 42 and may thus be involved in invasion/metastasis, or in endothelial cell adhesion. 43 It is also involved in drug metabolism within the liver. 44 Numerous SNPs that may affect function have been identified. 45 An intriguing finding in this study was that genetic variations in CHST3 were associated with both efficacy and toxicity, increasing the likelihood that this finding of association may indicate a role in docetaxel or thalidomide pharmacokinetics and/or pharmacodynamics. Further analyses into this gene and its possible role in drug pharmacology are warranted.
Sulfotransferase family, cytosolic, 1C, member 2 encodes a sulfotransferase that is thought to be involved in the metabolism of drugs and endogenous substrates, and is expressed both intra-and extra-hepatically as well as in the adult kidney. 46, 47 Genetic variation in this gene and other cytosolic sulfotransferases were recently reported.
48
SULT1C2 seems to be downregulated during breast cancer progression in which it may be involved with steroid hormone metabolism and detoxification reactions. 49, 50 Sulfation reactions are not known to be involved in the metabolism of docetaxel or thalidomide. Given the strong extrahepatic expression of SULT1C2, it is equally likely that SULT1C2 is involved in the bodily disposition toward these drugs through direct metabolism, or indirect metabolism of other endogenous/exogenous agents that influence the activity of docetaxel and/or thalidomide. It is also possible that these SNPs are merely related to disease state, and not drug activity.
Single-nucleotide polymorphisms in eight genes were found to be associated with docetaxel and thalidomide toxicities. SPG7 encodes a mitochondrial metalloprotease protein known as paraplegin. Genetic variations in SPG7 have been found in patients with spastic paraplegia, a degenerative neurological condition. 51 A closely related gene, SPG6, which is also associated with spastic paraplegia, was recently found to function as a transporter.
52 CYP2D6 and CYP4B1 are members of the P450 family of phase I metabolic enzymes. CYP2D6 is known to be involved in the metabolism of a wide range of drugs.
1 Inhibition of this enzyme was not found to affect the formation of hydroxyldocetaxel, which is thought to be mediated by CYP3A4. 53 Whether this enzyme is involved in the formation of other docetaxel metabolites is unknown. Human microsome studies did not find a significant role for CYP2D6 and other CYP enzymes in thalidomide metabolism. 54 It is also possible that certain CYP2D6 alleles may confer a multiple-chemical sensitivity phenotype that increases the likelihood of development of toxicities after drug treatment in general. Abbreviations: DMET, drug-metabolizing enzymes and transporters; SNP, singlenucleotide polymorphism. Individual genotyping results using DMET and direct sequencing were compared, and concordance between these two data sets was compared. A result of 100% indicates that the results were in complete agreement.
Pharmacogenetics of docetaxel and thalidomide N-acetyltransferase 2 (arylamine N-acetyltransferase) encodes a polymorphic drug and xenobiotic-metabolizing enzyme that acetylates substrates. Genetic variants in NAT2 can cause a 'slow', 'intermediate' or 'rapid' acetylator phenotype. These variants can predict efficacy and toxicity of a wide range of drugs, including sulfasalazine 56 and isoniazid. 57 ABCC6 encodes a xenobiotic transporter from the C subfamily of the ATP-binding cassette (ABC) family of transporters. ABCC6, also termed MRP6, is known to be involved in the transport of glutathione conjugates and may mediate drug resistance to agents, such as etoposide, teniposide, doxorubicin and daunorubicin.
58 ATP7A encodes a transporter that is characterized best for its role in copper disposition, and is also thought to mediate cisplatin and carboplatin transport and resistance. 59 Finally, SLC10A2 encodes a sodium-dependent transporter highly expressed in the ileum and liver involved in the enterohepatic circulation of bile acids. 60 Polymorphisms in these enzymes and transporters might alter the disposition toward xenobiotics in general, and could potentially be involved in pharmacokinetic and pharmacodynamic relationships with docetaxel and thalidomide. However, as the mechanism behind these associations is unclear, it is difficult to ascertain the importance of these findings. This is the first study to report that these enzymes and transporters may be involved in the disposition of docetaxel and thalidomide, and/or their metabolites. This raises the possibility that these results are false positives and reflect only random associations that are found to be statistically significant. The risk of false-positive findings can be common in pharmacogenetic research as more polymorphisms, combinations of polymorphisms or phenotypes are included in studies with limited number of study subjects. 61 Given the breath of the DMET platform, with 170 genes and 1256 polymorphisms, this was a potential shortcoming in our study. To reduce the risk of false-positive results, we restricted reported results to those in which the P-value was o0.01, using Mehta's modification to Fisher's exact test. As an exploratory study analyzing associations between SNPs and clinical parameters, this was meant to be hypothesis generating and provide targets for future-and largerpharmacogenetic clinical studies. 61 Research to confirm these exploratory findings are ongoing.
The promise of the emerging field of pharmacogenetics is that someday we may enter an era of 'individualized medicine' in which physicians can choose the right drug at the right dose for each patient. In no area of pharmacotherapy is this more important than in medical oncology. Given that we still only poorly understand the relative importance of enzymes and transporters involved in the pharmacokinetics of chemotherapy drugs, 1 the challenge facing pharmacogenetic and oncology researchers is the ability to screen for polymorphisms in many genes in order that we may better narrow our search for the key players in each drug's metabolic pathway.
We believe that a research strategy for understanding the pharmacogenetics of anticancer agents can be pursued using exploratory screening for polymorphisms that may correlate with pharmacokinetics and/or pharmacodynamics. These exploratory studies can then be followed by high-throughput analyses using larger clinical sample sets. 11, 61 New tools, such as the DMET platform, will make pharmacogenetic research available to more researchers, which may lead to answering clinical questions in medical oncology and other fields. This, in turn, may hasten the day when the promise of individualized pharmacogenetic therapy becomes a reality for more of our cancer patients.
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